PL444000A1 - Sposób leczenia i diagnozowania nowotworu z wykorzystaniem informacji o modyfikacjach epigenetycznych - Google Patents

Sposób leczenia i diagnozowania nowotworu z wykorzystaniem informacji o modyfikacjach epigenetycznych

Info

Publication number
PL444000A1
PL444000A1 PL444000A PL44400023A PL444000A1 PL 444000 A1 PL444000 A1 PL 444000A1 PL 444000 A PL444000 A PL 444000A PL 44400023 A PL44400023 A PL 44400023A PL 444000 A1 PL444000 A1 PL 444000A1
Authority
PL
Poland
Prior art keywords
cpg
cancer
type
subject
dmps
Prior art date
Application number
PL444000A
Other languages
English (en)
Inventor
Tomasz WOJDACZ
Jan Bińkowski
Olga Taryma-Leśniak
Original Assignee
Pomorski Uniwersytet Medyczny W Szczecinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pomorski Uniwersytet Medyczny W Szczecinie filed Critical Pomorski Uniwersytet Medyczny W Szczecinie
Priority to PL444000A priority Critical patent/PL444000A1/pl
Priority to EP24712954.7A priority patent/EP4677603A1/en
Priority to PCT/IB2024/052219 priority patent/WO2024184854A1/en
Publication of PL444000A1 publication Critical patent/PL444000A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Zgłoszenie dotyczy sposobu leczenia osobnika z nowotworem, obejmujący: a) identyfikowanie wielu cech nowotworu typu t opartych na sąsiadujących ze sobą parach CpG, przy czym wiele cech opartych na sąsiadujących ze sobą parach CpG ma łączną liczbę K cech opartych na sąsiadujących ze sobą parach CpG, przy czym K jest dodatnią liczbą całkowitą, zaś wspomnianymi cechami jest status metylacji w parach o różnicującym statusie metylacji DMP (ang. differential methylation pairs) wybranych na podstawie specyficzności statusu metylacji we wspomnianych DMP w co najmniej jednym typie próbek spośród co najmniej jednego z innych typów próbek; b) generowanie dyskryminacyjnego profilu metylacji opartego na parach CpG, dla komórki lub tkanki od osobnika zawartej w badanej próbce, przy czym dyskryminacyjny profil metylacji oparty na parach CpG zawiera pary o różnicującym statusie metylacji (DMP) wybrane na podstawie specyficzności statusu metylacji we wspomnianych DMP w co najmniej jednym typie próbki spośród co najmniej jednego z innych typów próbek, przy czym wspomniany profil zawiera koordynaty genomowe wspomnianych kolejnych DMP i pojedynczą wartość wskazującą na status metylacji dla wspomnianych DMP we wspomnianej badanej próbce; c) stwierdzanie, że osobnik ma nowotwór typu t, jeśli obliczony wynik predykcji λ, będący wynikiem porównania wspomnianego profilu metylacji opartego na parach CpG ze wspomnianymi wieloma cechami sąsiadujących ze sobą par CpG nowotworu typu t, jest większy niż wcześniej określona wartość progowa; oraz d) poddawanie osobnika leczeniu na podstawie stwierdzenia, że osobnik ma nowotwór typu t, przy czym leczenie obejmuje element wybrany z grupy składającej się z chemioterapii, radioterapii, immunoterapii i resekcji guza. Niniejszym ujawniono również sposób diagnozowania nowotworu u pacjenta.
PL444000A 2023-03-07 2023-03-07 Sposób leczenia i diagnozowania nowotworu z wykorzystaniem informacji o modyfikacjach epigenetycznych PL444000A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL444000A PL444000A1 (pl) 2023-03-07 2023-03-07 Sposób leczenia i diagnozowania nowotworu z wykorzystaniem informacji o modyfikacjach epigenetycznych
EP24712954.7A EP4677603A1 (en) 2023-03-07 2024-03-07 Methods, systems and assosiated computer program products for discriminating type of biological sample of an organism using epigenetic modification information
PCT/IB2024/052219 WO2024184854A1 (en) 2023-03-07 2024-03-07 Methods, systems and assosiated computer program products for discriminating type of biological sample of an organism using epigenetic modification information

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444000A PL444000A1 (pl) 2023-03-07 2023-03-07 Sposób leczenia i diagnozowania nowotworu z wykorzystaniem informacji o modyfikacjach epigenetycznych

Publications (1)

Publication Number Publication Date
PL444000A1 true PL444000A1 (pl) 2024-09-09

Family

ID=92676891

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444000A PL444000A1 (pl) 2023-03-07 2023-03-07 Sposób leczenia i diagnozowania nowotworu z wykorzystaniem informacji o modyfikacjach epigenetycznych

Country Status (1)

Country Link
PL (1) PL444000A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102891A2 (en) * 2005-11-08 2007-09-13 Euclid Diagnostics Llc Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
KR101384326B1 (ko) * 2013-09-06 2014-04-10 이화여자대학교 산학협력단 ＮＴＮ4 유전자의 ＣｐＧ 메틸화 변화를 이용한 난소암 전이 진단용 조성물 및 이의 이용
WO2015034289A1 (ko) * 2013-09-06 2015-03-12 이화여자대학교 산학협력단 유전자의 CpG 메틸화 변화를 이용한 난소암 전이 진단용 조성물 및 이의 이용
WO2016115530A1 (en) * 2015-01-18 2016-07-21 The Regents Of The University Of California Method and system for determining cancer status

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102891A2 (en) * 2005-11-08 2007-09-13 Euclid Diagnostics Llc Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
KR101384326B1 (ko) * 2013-09-06 2014-04-10 이화여자대학교 산학협력단 ＮＴＮ4 유전자의 ＣｐＧ 메틸화 변화를 이용한 난소암 전이 진단용 조성물 및 이의 이용
WO2015034289A1 (ko) * 2013-09-06 2015-03-12 이화여자대학교 산학협력단 유전자의 CpG 메틸화 변화를 이용한 난소암 전이 진단용 조성물 및 이의 이용
WO2016115530A1 (en) * 2015-01-18 2016-07-21 The Regents Of The University Of California Method and system for determining cancer status

Similar Documents

Publication Publication Date Title
Huebner et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma
Meldi et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
McMillan et al. Drain management after pancreatoduodenectomy: reappraisal of a prospective randomized trial using risk stratification
Tessier et al. Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer?
Crippa et al. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology
Margolin et al. Robust detection of DNA hypermethylation of ZNF154 as a pan-cancer locus with in silico modeling for blood-based diagnostic development
US12467097B2 (en) DNA methylation marker for predicting recurrence of liver cancer, and use thereof
Wang et al. Identification and verification of the ferroptosis-and pyroptosis-associated prognostic signature for low-grade glioma
Angulo et al. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guerin
Milojevic et al. Upper urinary tract transitional cell carcinoma: location is not correlated with prognosis.
Dunn et al. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer
CA3154902A1 (en) Cancer detection methods
Kim et al. The impact of perioperative CA19‐9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma
Lee et al. Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia
Sandro et al. Lymph-node ratio in patients with cutaneous melanoma: a multi-institution prognostic study
Hendrickson-Rebizant et al. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer
PL444000A1 (pl) Sposób leczenia i diagnozowania nowotworu z wykorzystaniem informacji o modyfikacjach epigenetycznych
KR102698507B1 (ko) Cell-free DNA 를 이용한 건강 및 질병관리 시스템 및 방법
Kawashima et al. “Biological R2” resection for intrahepatic cholangiocarcinoma: identification of patients at risk for poor oncologic outcomes after curative-intent resection
Kim et al. Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings
Thomas et al. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit
Komatsu et al. Impact of perioperative chemotherapy on prognosis of patients with esophageal carcinoma undergoing pulmonary metastasectomy
Harada et al. Methylated DLX4 predicts response to pathologic stage I non-small cell lung cancer resection
Jonker et al. Epigenetic dysregulation in adrenocortical carcinoma, a systematic review of the literature
An et al. Low RPMB indicates better disease-free survival of adjuvant radiotherapy after radical surgery in thymoma